Home/Pipeline/iNK Platform Programs

iNK Platform Programs

Hematological and Solid Tumors

Pre-clinicalActive

Key Facts

Indication
Hematological and Solid Tumors
Phase
Pre-clinical
Status
Active
Company

About Shoreline Biosciences

Shoreline Biosciences is a private, pre-clinical stage biotech founded in 2020 and headquartered in San Diego, CA. The company is pioneering a platform for developing homogeneous, scalable, 'off-the-shelf' cellular immunotherapies using engineered iPSC-derived natural killer cells and macrophages. Its approach aims to overcome key limitations of autologous cell therapies, such as manufacturing complexity, high cost, and product variability. Shoreline is building a pipeline of candidates targeting cancer and other serious diseases, positioning itself in the competitive but high-potential allogeneic cell therapy space.

View full company profile

Therapeutic Areas

Other Hematological and Solid Tumors Drugs

DrugCompanyPhase
CAR-T Program(s)CellurisPre-clinical / Early Clinical
Not DisclosedONK TherapeuticsPreclinical
CAR-iNKT ProgramsMiNK TherapeuticsPreclinical